NovImmune is actively seeking to explore opportunities for in- and out-licensing collaborations with pharmaceutical, biotechnology, and academic partners for novel proprietary therapeutic monoclonal antibodies and targets. Proprietary targets with extensive biological validation will obviously be preferred. However, NovImmune is prepared to conduct all such activities.

Licensing-out IP

NovImmune owns IP on the role of statins as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent. NovImmune has a number of individual patent applications covering various specific autoimmune diseases.

For more information, please contact busdev@novimmune.com